Novo Nordisk reported DKK239.08B in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
Bausch Health Companies USD 4.75B 205M Sep/2026
Bristol-Myers Squibb USD 18.75B 94M Sep/2026
Eli Lilly USD 47B 745M Sep/2026
GlaxoSmithKline GBP 20.72B 814M Sep/2026
Merck USD 28.8B 1.07B Sep/2026
Novartis USD 32.52B 777M Sep/2026
Novo Nordisk DKK 239.08B 13.92B Jun/2026
Novo Nordisk DKK 36.54B 188.62B Jun/2026
Pacira USD 126.1M 4.08M Sep/2026
Sanofi EUR 29.77B 2.16B Sep/2026
Supernus Pharmaceuticals USD 285.4M 61.98M Sep/2026